Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Do you recommend treatment for CLL patients with biopsy proven infiltrative lesions in the liver without hepatic dysfunction or hepatomegaly?
Related Questions
Would you consider TKI discontinuation in a patient who has negative BCR transcripts on Bosutinib?
What are your top takeaways in Hematologic Malignancies from ASCO 2023?
For AML patients, when do you stop antiinfective agents?
How should one approach an incidentally found T-cell gene arrangement?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
Would you re challenge a CLL patient, who had good response to Zanubrutinib but contracted cryptococcal pneumonia, with another TKI?
Do you prefer quizartinib over midostaurin with chemotherapy induction for FLT3-ITD mutated AML given the results of QUANTUM-FIRST and preclinical advantages over other FLT3 inhibitors?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?
